Universe Pharmaceuticals Inc. cash flow to debt ratio of -54.58% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Universe Pharmaceuticals Inc.'s free cash flow has increased -45.29% from $-9.87M last year to $-5.40M, signaling increasing performance

Universe Pharmaceuticals Inc.'s debt to equity ratio is 0.17, which means that the company's assets are healthy financed, signaling financial stability.

Universe Pharmaceuticals Inc.'s debt has decreased relative to shareholder equity from 0.18 last year to 0.17 today, signaling strengthened financials

Universe Pharmaceuticals Inc. has a net cash position, so leverage is healthy.

Universe Pharmaceuticals Inc.'s interest coverage ratio is -9.11, which means that the company struggles to meet interest obligations, signaling financial risk.

Universe Pharmaceuticals Inc.'s profit margin has increased (-71.12%) in the last year from -37.90% to -10.95%, signaling increasing performance

Universe Pharmaceuticals Inc.'s short-term assets of $53.60M exceed its short-term liabilities of $13.17M

Universe Pharmaceuticals Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Universe Pharmaceuticals Inc.'s return on equity of -3.48%, is lower than 15.00%, indicating bad performance

Universe Pharmaceuticals Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Universe Pharmaceuticals Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Universe Pharmaceuticals Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Universe Pharmaceuticals Inc. has negative free cash flow, indicating cash burn

Universe Pharmaceuticals Inc.'s yearly earnings has increased -57.92% since last year from $-8.73M to $-3.67M, signaling increasing performance

Universe Pharmaceuticals Inc.'s yearly revenue has decreased 22.44% since last year from $23.02M to $17.86M, signaling decreasing performance

ROIC -3.20% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Universe Pharmaceuticals Inc.'s 3-year revenue CAGR of -23.66% is negative, indicating declining revenue over the past 3 years

Universe Pharmaceuticals Inc. had revenue growth in only 1 out of 5 years, indicating inconsistent revenue performance

Universe Pharmaceuticals Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Universe Pharmaceuticals Inc. has insufficient data to evaluate this check.

Universe Pharmaceuticals Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Universe Pharmaceuticals Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Universe Pharmaceuticals Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Universe Pharmaceuticals Inc. is overvalued relative to its fair value price of -5.63K based on Earnings Fair Value model

Universe Pharmaceuticals Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Universe Pharmaceuticals Inc. has a price-to-book ratio of 0.07x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Universe Pharmaceuticals Inc. has a price-to-sales ratio of 0.23x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue